Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

Flagship Pioneering startup lays off a third of staff

Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering companies, has laid off about a third of its staff.

February 16, 2024

AI assistance in radiology shows mixed results for performance

One of the most touted promises of medical artificial intelligence tools is their ability to augment human clinicians’ performance by helping them interpret images such

March 20, 2024

Interactomics-based analysis suggests that rhinitis and rhinitis with asthma are mechanistically different diseases

Researchers used human transcriptomic data to differentiate the molecular mechanisms associated with two phenotypes of allergic rhinitis: rhinitis and rhinitis with asthma.

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.